期刊文献+

hTR-siRNA腺病毒对裸鼠人宫颈癌移植瘤的治疗作用 被引量:1

Therapeutic Effects of hTR-siRNA Adenovirus on Human Cervical Cancer Xenografts in Nude Mice
下载PDF
导出
摘要 目的探讨人端粒酶RNA(hTR)-siRNA腺病毒对裸鼠人宫颈癌移植瘤的治疗作用及其机制。方法将HeLa细胞注射到裸鼠的右腋皮下建立肿瘤模型,27d后将荷瘤裸鼠随机分为4组,采用瘤体内多点注射方式,分别向各组荷瘤鼠注射0.1mL的DMEM、Ad-NT-siRNA(1013pfu/L)、Ad-hTR-siRNA(1013pfu/L)或顺铂(1.20g/L),以后每隔3d注射1次,连续15d。观察注射腺病毒后移植瘤的体积变化、毒副作用。治疗结束后间隔7d处死动物,剥离出肿瘤组织称重。切取瘤组织做TUNEL染色测定组织的凋亡指数。结果将HeLa细胞移植到裸鼠皮下,成瘤率为100%。与Ad-NT-siRNA处理组相比,Ad-hTR-siRNA处理组的裸鼠移植瘤的体积和质量分别降低45.48%和34.68%,TUNEL分析显示凋亡细胞量约11.8%;但是Ad-hTR-siRNA的抗肿瘤作用不及顺铂。结论hTR-siRNA腺病毒能够明显抑制裸鼠人宫颈癌移植瘤的生长,其抗肿瘤机制与诱导肿瘤细胞凋亡、坏死有关。 Objective To study the anti-tumor effects and its mechanism of hTR-siRNA adenovirus on human cervical cancer in vivo. Methods The in vivo model of human cervical cancer was established by the subcutaneous inoculation of HeLa cells at the right armpit of BALB/e nu/nu mice. After successful implantation, the mice were randomized into four groups, in which the mice were intratumorally injected with 0. 1 mL of Ad- hTR-siRNA (10is pfu/L),or Ad-NT-siRNA (1013 pfu/L), or Cisplatin (1. 20 g/L), or serum-free DMEM alone respectively. These treatments were given once every 3 days for 6 times. After the last injection, the mice were observed for 7 days continuously and sacrificed at the end. The tumors were harvasted, weighed, and sectioned. The TUNEL assay was used to assess the apoptosis of these tumor cells. Results Tumors-implanted were established successfully by 100% with HeLa cells. As compared with Ad-NT-siRNA, Ad-hTR-siRNA could slow down tumor growth, decrease tumor volume (45. 48%) and tumor weight (34. 68%), as well as promote the apoptosls and necrosis of tumor cells. The TUNEL positive ceils were about 11.8%. But the anti-tumor activity of Ad-hTR-siRNA didn't catch on Cisplatin's. Conclusion This study indicated that the hTR-siRNA adenovirus could suppress cervical cancer-xenografted growth in vivo and induce tumor cell apoptosis or necrosis.
出处 《四川大学学报(医学版)》 CAS CSCD 北大核心 2008年第5期711-714,731,共5页 Journal of Sichuan University(Medical Sciences)
基金 教育部博士点基金(20040610050)资助
关键词 宫颈癌 腺病毒 RNA干扰 HTR基因 Cervical cancer Adenovirus RNA interference Human telomerase RNA
  • 引文网络
  • 相关文献

参考文献10

  • 1Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumori-genlcity by virus-mediated RNA interference. Cancer Cell,2002;2(3) :243-247.
  • 2Takao T, Yosuke A, Yasuyuki S, et al. Constitutive activation of STAT3 in lung cancer: stable retrovirus-mediated RNA interference against STAT3 inhibited the in vitro growth of lung cancer. Proc Amer Assoc Cancer Res,2006,47:966- 970.
  • 3Osada H, Tatematsu Y, Yatabe Y, et al. ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res,2005;65:10680-10685.
  • 4Hemann MT, Fridman JS, Zilfou JT, et al. An epi-allellc series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet,2003,33:396- 400.
  • 5Chen Y, Chen H, Hoffmann A, et al. Adenovirus-mediated small-interference RNA for in vivo silencing of angiotensin ATla receptors in mouse brain. Hypertension, 2006; 47: 230- 237.
  • 6Dinah WYS. Therapeutic potential of RNA interference for neurological disorders. Life Sci, 2006 ; 79 : 1773-1780.
  • 7李燕,肖丽英,姚刚,李虹,杨志伟,李婉宜,蒋忠华,李明远.hTR-siRNA腺病毒的构建及其体外抗肿瘤的初步研究[J].细胞与分子免疫学杂志,2008,24(6):570-573. 被引量:2
  • 8Zhang X, Kon T, Wang H. Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor- 3.alpha. Cancer Res,2004;64(22) :8139-8142.
  • 9Huang Q, Zhang X, Wang H, et al. A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin Cancer Res,2004;10(4):1439-1445.
  • 10Cepeda V, Fuertes MA, Castilla J, et al. Biochemical mechanisms of cisplatin cytotoxiclty. Anticancer Agents Med Chem,2007,7(1) :3-9.

二级参考文献10

  • 1杨健,胡为民,任碧轩,唐恩洁.RNA干扰体外抑制HBeAg的表达[J].细胞与分子免疫学杂志,2006,22(5):670-671. 被引量:5
  • 2吴涛,石宝晨,陈润生.RNA干涉现象的发现与研究进展——2006年诺贝尔生理学或医学奖简介[J].生物化学与生物物理进展,2006,33(10):915-917. 被引量:6
  • 3Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference[ J]. Cancer Cell, 2002, 2 (3) : 243 - 247.
  • 4Feng J, Funk WD, Wang SS, et al. The RNA component of human telomerase[ J]. Science, 1995, 269(5228) : 1236 - 1241.
  • 5Mizuguchi H, Kay MA. Efficient construction of a recombinant adenovirus by an improved in vitro ligation method [ J ]. Hum Gene Ther, 1998, 9(17): 2577-2583.
  • 6Kosciolek BA, Kalantidis K, Tabler M, et al. Inhibition of telomerase activity in human cancer cells by RNA interference [ J ]. Mol Cancer Ther, 2003, 2: 209- 216.
  • 7Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) ) Method [ J]. Methods, 2001,25(4): 402-408.
  • 8Mizuguchi H, Kay MA, Hayakawa T. Approaches for generating recombinant adenovirus vectors [ J ]. Adv Drug Deliv Rev, 2001, 52 (3) : 165 -176.
  • 9Binz N, Shalaby T, Rivera P, et al. Telomerase inhibition, telomere shortening, cell growth suppression and induction of apoptosis by telomestatin in childhood neuroblastoma cells [ J ]. Eur J Cancer, 2005, 41(18): 2873-2881.
  • 10何冬梅,张洹.端粒酶基因反义核酸下调HL-60细胞端粒酶活性的研究[J].癌症,2002,21(10):1070-1074. 被引量:6

共引文献1

同被引文献35

  • 1韩庆旺,樊燕蓉,傅更锋,刘新卷,徐根兴.RNA干扰对VEGF在人卵巢癌细胞中表达及细胞增殖的影响[J].第二军医大学学报,2005,26(9):992-996. 被引量:6
  • 2朱晓应,符伟军,洪宝发.端粒酶与肿瘤靶向治疗[J].国外医学(遗传学分册),2005,28(6):366-368. 被引量:7
  • 3丁昂,童赛雄,冯平,秦新裕.hTERT-siRNA抑制胆囊癌细胞端粒酶活性及增殖运动的研究[J].武汉大学学报(医学版),2006,27(3):287-290. 被引量:3
  • 4Burger AM. Highlights in experimental therapeutics [J]. Cancer Lett,2007,245 ( 1/2) : 11-21.
  • 5Bravaccini S, Casadio V, Amadori D, et al. The current role of telomerase in the diagnosis of bladder cancer [J]. Indian J Urol, 2009,25( 1 ) :40-46.
  • 6Kim NW, Patyszek MA, Prowse KR,et al. Specific association of human telomerase activity with immortal cells and cancer[ J ]. Sci- ence, 1994,266 (5193 ) :2011-2015.
  • 7Hiyama E, Kodama T, Shinbara K, et al. Telomerase activity is detected in pancreatic cancer but not in benign tumors[ J]. Cancer Res,1997,57 (2) :326-331.
  • 8Liu J, Carmell MA, Rivas FV, et al. Argonaute 2 is the catalytic engine of mammalian RNAi [J]. Science, 2004, 305 ( 5689 ) : 1437-1d41.
  • 9Bae DS, Cho SB,Kim YJ,et al. Aberrant expression of cylin D1 is associated with poor prognosis in early stage cervical cancer of the uterus [ J ]. Gynecol Oneo1,2001,81 ( 3 ) : 341-347.
  • 10Irluang R, Zhao Z, Ma X, et al. Targeting of tumor radioiodine thera- py by expression of the sodium iodide symporter under control of the survivin promoter[J]. Cancer Gene Ther,2011,18 (2) : 144-152.

引证文献1

;
使用帮助 返回顶部